Equillium, Inc. (NASDAQ:EQ) Short Interest Update

Equillium, Inc. (NASDAQ:EQ) was the target of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 117,600 shares, a decline of 46.1% from the October 15th total of 218,000 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average daily trading volume, of 184,500 shares, the short-interest ratio is presently 0.6 days.

Insider Buying and Selling at Equillium

In other Equillium news, insider Penny Tom sold 38,806 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $0.85, for a total transaction of $32,985.10. Following the transaction, the insider now directly owns 10,051 shares in the company, valued at $8,543.35. This represents a 79.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 67,324 shares of company stock worth $64,233 over the last 90 days. Company insiders own 30.30% of the company’s stock.

Institutional Trading of Equillium

An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC grew its holdings in Equillium, Inc. (NASDAQ:EQ) by 43.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 300,400 shares of the company’s stock after purchasing an additional 91,200 shares during the quarter. Renaissance Technologies LLC owned about 0.85% of Equillium worth $208,000 as of its most recent SEC filing. 27.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Equillium in a research report on Monday, August 19th.

Equillium Stock Performance

Shares of NASDAQ:EQ traded down $0.10 during midday trading on Thursday, reaching $0.68. 363,866 shares of the company’s stock traded hands, compared to its average volume of 270,624. The company has a market cap of $24.24 million, a P/E ratio of -4.89 and a beta of 1.83. The company has a fifty day simple moving average of $0.92 and a two-hundred day simple moving average of $0.98. Equillium has a 1 year low of $0.48 and a 1 year high of $3.25.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.